WallStreetZenWallStreetZen
Analyst Ranking
Bottom 8%
#3904 out of 4237 analysts
Average Return
-5.2%
Win Rate
40%24 out of 60
Risk vs Reward
Poor
Good

David Turkaly's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Si Bone IncSIBN
+107.72%$12.69$26.36
2022-11-08 -
2023-06-02
Buy
Icad IncICAD
+99.77%$8.88$17.74
2020-02-05 -
2021-02-05
Buy
Steris PLCSTE
+34.16%$114.74$153.94
2018-08-09 -
2019-08-09
Buy
Haemonetics CorpHAE
+34.12%$61.51$82.50
2021-11-10 -
2022-11-09
Buy
Tela Bio IncTELA
+30.74%$8.10$10.59
2022-11-10 -
2023-06-02
Buy

David Turkaly Analyst Color

Get additional color on David Turkaly's coverage of popular stocks

David Turkaly's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Lantheus Holdings IncLNTH
3Buy$130.00+46.61%Reiterates
4 days ago
Integra Lifesciences Holdings CorpIART
6Buy$65.00+66.92%Reiterates
10 days ago
Haemonetics CorpHAE
5Buy$115.00+30.49%Maintains
24 days ago
Steris PLCSTE
5Buy$240.00+16.81%Reiterates
25 days ago
Neuronetics IncSTIM
3Buy$12.00+342.80%Reiterates
a month ago
Axogen IncAXGN
3Buy$20.00+126.24%Reiterates
a month ago
Teleflex IncTFX
6Buy$330.00+39.55%Reiterates
a month ago
Paragon 28 IncFNA
3Buy$30.00+61.99%Reiterates
a month ago
Zimmer Biomet Holdings IncZBH
8Buy$160.00+23.26%Maintains
a month ago
Si Bone IncSIBN
4Buy$32.00+21.40%Reiterates
a month ago
Orthopediatrics CorpKIDS
3Buy$60.00+32.60%Reiterates
a month ago
Nevro CorpNVRO
4Buy$75.00+165.30%Reiterates
a month ago
Icad IncICAD
4Buy$4.00+207.69%Maintains
2 months ago
Tela Bio IncTELA
2Buy$20.00+88.86%Reiterates
2 months ago
Apyx Medical CorpAPYX
1Buy$14.00N/AMaintains
2 years ago
Cognyte Software LtdCGNT
1Buy$5.00N/AInitiates Coverage On
6 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.